Clinical Ink is a global life science company that brings data, technology, and patient science together. Clinical Ink’s platform is powered by deep therapeutic-area expertise, coupled with Direct Data Capture (DDC), electronic clinical outcome assessment (eCOA), eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, ushering in a new generation of clinical trials. By harnessing digital data, the company enables sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.
Initial Investment Date: August 2020
GI Role: Lead Investor